About neuro42
neuro42 is a medical technology company that has developed a specialized portable magnetic resonance imaging (MRI) platform designed specifically for the neurological care landscape. Unlike traditional high-field MRI scanners that are stationary and require massive facility shielding, this system is a low-field, mobile unit that can be brought directly to the patient's bedside or into a surgical suite. By integrating artificial intelligence and robotics into a single platform, the tool aims to make neuroimaging more accessible, less disruptive, and more functional for real-time clinical decision-making.
The platform operates on an FDA 510(k) cleared system that combines high-resolution imaging with automated tools for enhanced diagnostic accuracy. It utilizes AI to assist in image acquisition and provides robotic guidance for minimally invasive neurosurgical procedures, such as tumor resections, biopsies, and Deep Brain Stimulation (DBS). The system's portable footprint allows it to be used in diverse environments, including intensive care units (ICUs), emergency rooms, and surgical centers. This mobility eliminates the physical risks and time delays associated with transporting unstable patients to a separate radiology department, facilitating immediate monitoring and rapid intervention.
The tool is primarily designed for neurosurgeons, radiologists, and critical care specialists working in comprehensive stroke centers, hospitals, and outpatient clinics. It is particularly beneficial for managing patients who are too unstable for transport or those requiring intraoperative imaging to confirm successful surgical outcomes. Additionally, the technology is suited for healthcare facilities looking to expand their imaging capabilities without the heavy infrastructure costs of traditional MRI rooms, offering a more flexible "concierge" model of neuro-focused care.
What makes neuro42 unique is the synergy of low-field MRI with integrated robotics and AI in a single, mobile unit. While other portable imaging solutions exist, this platform emphasizes interventional guidance, allowing physicians to perform complex procedures with greater precision. Supported by over 40 patents and a growing database of successful scans, the platform transitions MRI from a purely diagnostic tool to a real-time interventional partner, significantly reducing the barrier to advanced neurological care for both patients and providers.
neuro42 FAQs
Is the neuro42 platform FDA cleared?
Yes, the neuro42 MRI platform is FDA 510(k) cleared. This clearance ensures the technology meets the safety and effectiveness standards required for clinical neurological imaging and interventions.
What kind of procedures can the platform support?
The platform is designed to assist in confirming tumor resections and supporting stereotactic interventions. These include biopsies, laser treatments, and Deep Brain Stimulation (DBS) with real-time imaging guidance.
Where can the neuro42 system be used within a hospital?
Due to its portability and low-field technology, the system can be deployed in ICUs, emergency rooms, surgical suites, and outpatient clinics. It does not require the heavy shielding of traditional MRI rooms.
How does AI and robotics improve the imaging process?
The integrated AI assists in image analysis and acquisition, while the robotic component provides precision guidance for minimally invasive procedures. Together, they reduce human error and improve procedural accuracy.
